Navigation Links
Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
Date:11/28/2007

Acquisition of Remainder of NexGen Diagnostics Captures Promising

Intellectual Property

FULLERTON, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer of products that simplify and automate complex biomedical testing announced today that it has entered into an agreement to acquire the remaining 80.1 percent of NexGen Diagnostics LLC, a spin out of Lumigen, Inc., effected prior to Beckman Coulter's acquisition of Lumigen in 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

Since NexGen's assets consist of intellectual property unrelated to current products, Beckman Coulter expects to take a charge of approximately $36 million for in-process R&D when the acquisition closes in the fourth quarter of 2007. The technologies have the potential to revolutionize high sensitivity testing, including immunoassay and nucleic acid, due to their inherently superior speed and simplicity.

Richard Creager, corporate vice president of Beckman Coulter's Immunoassay Business Center, said, "We are very enthusiastic about the potential that these proprietary technologies have to improve patient health and reduce the cost of care. If fully realized, they will simplify and automate certain types of immunodiagnostic and nucleic acid testing in remarkable ways, dramatically enhancing the performance of assays and accelerating turn-around time of test results."

The dramatic improvement in turn-around time is a result of a proprietary non-separation immunoassay technology which eliminates time-consuming steps while maintaining the exquisite sensitivity of the assays. Consistent with the company's commitment to develop a sample to result molecular testing system for clinical diagnostics, the acquired nucleic acid technology will allow rapid isolation of DNA or RNA from a patient sample without a separate step or reagent.

About Beckman Coulter, Inc.

Based in Fullerton, California, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue consisting of supplies, test kits, service and operating-type lease payments represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the contribution of the acquired technology to Beckman Coulter's R&D and product development capability. These statements are based on current expectations and assumptions. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond Beckman Coulter's control. Factors that affect the development of new technologies are described in Beckman Coulter's 10-K report filed with the SEC on February 26, 2007 and its 10-Q reports and other SEC filings.

Contacts:

Mary Luthy, Beckman Coulter Robert Raynor, Beckman Coulter

Corporate Communications Investor Relations

(714) 773-7964 (714) 773-7620


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
10. Neogen Acquires Kane Enterprises
11. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- Cousins Properties (NYSE: CUZ ) announced today ... signed a 10-year, approximately 125,000 square-foot lease at Corporate Center, ... the Westshore submarket of Tampa, FL. ... Corporate Center for their new location in Tampa ... executive officer of Cousins Properties. "Amgen is a cutting-edge global ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics Officer ... Subha Madhavan , Ph.D., will be speaking at ... Panels. On Monday, March 27, 2017, she will be ... More Usable for Research and Care" (from 10:30 a.m. ... 2017, she will be a participant in the "Making ...
(Date:3/27/2017)... ... ... PMG Research is pleased to announce its participation in the 2nd ... Boston on April 3-4, 2017. The CTC conference focuses on how the industry is ... closer to the patient. Clinical Trial Collaborations also will present an inaugural conference on ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):